Literature DB >> 19266573

Activation of NOD2-mediated intestinal pathway in a pediatric population with Crohn's disease.

Anna Negroni1, Laura Stronati, Maria Pierdomenico, Donatella Tirindelli, Giovanni Di Nardo, Valentina Mancini, Giulia Maiella, Salvatore Cucchiara.   

Abstract

BACKGROUND: NOD2 is an intracellular protein involved in host recognition of specific bacterial molecules and is genetically associated with several inflammatory diseases, including Crohn's disease (CD). NOD2 stimulation activates the transcription factor, NF-kappaB, through RIP2, a caspase-recruitment domain-containing kinase. NOD2/RIP2 signaling also mediates the activation of antimicrobial peptides such as human alpha-defensin 5 (HD-5) and human alpha-defensin 6 (HD-6), both produced by Paneth cells. The present study is aimed at describing the downstream events triggered specifically by NOD2 induction in order to demonstrate that the protein, other than overexpressed, is also physiologically associated with RIP2 and Erbin in the bioptic intestinal inflamed specimens of children affected by CD.
METHODS: Fifteen children with CD and 10 children used as controls were entered in the study. Mucosal biopsy specimens were taken during endoscopy and mRNA and protein expressions were detected by using real-time polymerase chain reaction and Western blot.
RESULTS: NOD2 is able to form an immunocomplex with the kinase RIP2. As compared to controls, in the inflamed mucosa of patients both mRNA and protein expression levels of RIP2 are increased, and its active phosphorylated form is overexpressed.
CONCLUSIONS: In this study we provide for the first time ex vivo evidence of physiologically relevant protein interactions with NOD2, which are able to trigger the innate immune response in intestinal mucosal specimens of children with CD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19266573     DOI: 10.1002/ibd.20907

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  22 in total

1.  RICK/RIP2 is a NOD2-independent nodal point of gut inflammation.

Authors:  Tomohiro Watanabe; Kosuke Minaga; Ken Kamata; Toshiharu Sakurai; Yoriaki Komeda; Tomoyuki Nagai; Atsushi Kitani; Masaki Tajima; Ivan J Fuss; Masatoshi Kudo; Warren Strober
Journal:  Int Immunol       Date:  2019-09-18       Impact factor: 4.823

2.  Nucleotide-binding oligomerization domain (NOD) signaling defects and cell death susceptibility cannot be uncoupled in X-linked inhibitor of apoptosis (XIAP)-driven inflammatory disease.

Authors:  Steven M Chirieleison; Rebecca A Marsh; Prathna Kumar; Joseph K Rathkey; George R Dubyak; Derek W Abbott
Journal:  J Biol Chem       Date:  2017-04-12       Impact factor: 5.157

3.  Control of NOD2 and Rip2-dependent innate immune activation by GEF-H1.

Authors:  Yun Zhao; Carmen Alonso; Isabel Ballester; Joo Hye Song; Sun Young Chang; Bayasi Guleng; Seiji Arihiro; Peter J Murray; Ramnik Xavier; Koichi S Kobayashi; Hans-Christian Reinecker
Journal:  Inflamm Bowel Dis       Date:  2011-09-01       Impact factor: 5.325

4.  Functional defects in NOD2 signaling in experimental and human Crohn disease.

Authors:  Daniele Corridoni; Kristen O Arseneau; Fabio Cominelli
Journal:  Gut Microbes       Date:  2014-03-05

5.  In vivo inhibition of RIPK2 kinase alleviates inflammatory disease.

Authors:  Justine T Tigno-Aranjuez; Pascal Benderitter; Frederik Rombouts; Frederik Deroose; XiaoDong Bai; Benedetta Mattioli; Fabio Cominelli; Theresa T Pizarro; Jan Hoflack; Derek W Abbott
Journal:  J Biol Chem       Date:  2014-09-11       Impact factor: 5.157

6.  Effect of bifidobacterium on defensin-5 expression in intestinal injury of preweaning rats.

Authors:  Wei Wang; Shu-Fen Yang; Li-Hong Ren; Xiu-Xiu Zhang; Shui-Lian Yu
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

7.  Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses.

Authors:  Justine T Tigno-Aranjuez; John M Asara; Derek W Abbott
Journal:  Genes Dev       Date:  2010-12-01       Impact factor: 11.361

8.  Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors.

Authors:  Curt D Haffner; Adam K Charnley; Christopher J Aquino; Linda Casillas; Máire A Convery; Julie A Cox; Mark A Elban; Nicole C Goodwin; Peter J Gough; Pamela A Haile; Terry V Hughes; Beth Knapp-Reed; Constantine Kreatsoulas; Ami S Lakdawala; Huijie Li; Yiqian Lian; David Lipshutz; John F Mehlmann; Michael Ouellette; Joseph Romano; Lisa Shewchuk; Arthur Shu; Bartholomew J Votta; Huiqiang Zhou; John Bertin; Robert W Marquis
Journal:  ACS Med Chem Lett       Date:  2019-10-11       Impact factor: 4.345

Review 9.  The immunology of host defence peptides: beyond antimicrobial activity.

Authors:  Robert E W Hancock; Evan F Haney; Erin E Gill
Journal:  Nat Rev Immunol       Date:  2016-04-18       Impact factor: 53.106

Review 10.  RIP2 activity in inflammatory disease and implications for novel therapeutics.

Authors:  Janice C Jun; Fabio Cominelli; Derek W Abbott
Journal:  J Leukoc Biol       Date:  2013-06-21       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.